What are the indications, dosing regimen, premedication, monitoring requirements, and contraindications for pegloticase in adults with chronic refractory gout?

Pegloticase for Chronic Refractory Gout

Pegloticase should be reserved exclusively for patients with chronic gout who have failed or cannot tolerate conventional urate-lowering therapies—it is strongly contraindicated as first-line treatment. 1

Indications

Pegloticase is indicated for chronic gout in adults who are refractory to conventional therapy, defined as patients who have:

• Failed to normalize serum uric acid with xanthine oxidase inhibitors (allopurinol, febuxostat) at maximum medically appropriate doses, OR
• Have contraindications to these medications 2

Critical limitation: Pegloticase is NOT recommended for asymptomatic hyperuricemia 2

The 2020 ACR guidelines explicitly state a strong recommendation against pegloticase as first-line therapy despite moderate evidence supporting its efficacy, citing cost, safety concerns, and more favorable benefit-to-harm ratios of other untried treatment options 1.

Dosing Regimen

Standard dosing: 8 mg intravenously every 2 weeks 2

• Administer as an intravenous infusion over no less than 120 minutes via gravity feed, syringe-type pump, or infusion pump 2
• Never administer as IV push or bolus 2
• Recent evidence suggests 60-minute infusions may be feasible when co-administered with methotrexate, showing comparable safety and efficacy 3

Discontinue all oral urate-lowering agents (allopurinol, febuxostat, probenecid) before starting pegloticase 2

Premedication Requirements (MANDATORY)

All patients must receive premedication with antihistamines AND corticosteroids before each infusion 2

Corticosteroid Options:

• Methylprednisolone is superior to hydrocortisone for pre-infusion prophylaxis based on real-world data showing patients received significantly more infusions (8.5 vs 4.9) and had fewer early terminations due to infusion reactions (8.2% vs 41.9%) 4
• The FDA label specifies corticosteroids without mandating a specific agent 2

Gout Flare Prophylaxis:

Mandatory for at least 6 months unless medically contraindicated or not tolerated 2

• Options: NSAIDs, colchicine, or low-dose prednisone/prednisolone
• Gout flares frequently occur upon initiation but do NOT require discontinuation of pegloticase 2

Immunomodulatory Co-therapy:

Emerging evidence strongly supports concomitant methotrexate to reduce anti-drug antibody formation:

• Improves pegloticase persistence (adjusted HR for discontinuation: 0.52) 5
• Increases urate-lowering response rate to 86-92% 6
• Can be used safely even in CKD patients with dose adjustment (mean 14.8 mg/week in CKD vs 19.3 mg/week in non-CKD) 6

Monitoring Requirements

Before Each Infusion:

Monitor serum uric acid levels prior to every infusion 2

Critical decision point: Consider discontinuing treatment if serum uric acid rises above 6 mg/dL, particularly when 2 consecutive levels above 6 mg/dL are observed 2

• Loss of urate-lowering response indicates anti-drug antibody formation and significantly increases infusion reaction risk 2

During and After Infusion:

• Administer only in healthcare settings with providers prepared to manage anaphylaxis 2
• Monitor closely for an appropriate period after administration for anaphylaxis 2
• Most anaphylaxis manifests within 2 hours, but delayed hypersensitivity reactions have been reported 2

Laboratory Monitoring:

Watch for (though uncommon <5%):

• White blood cell count <3.4 × 10⁹/L
• Platelet count <135,000
• Hematocrit <30%
• Liver enzymes ≥1.5 times upper limit normal 5

Contraindications

Absolute Contraindication:

Glucose-6-phosphate dehydrogenase (G6PD) deficiency 2

• Screen all patients at higher risk (African and Mediterranean ancestry) before initiating treatment 2
• Risk of hemolysis and methemoglobinemia 2

Relative Contraindications/Cautions:

Congestive heart failure: Exercise extreme caution

• Pegloticase has not been formally studied in CHF patients 2
• In clinical trials, 2% of patients receiving biweekly dosing experienced CHF exacerbation 7
• Monitor patients closely following infusion 2

Safety Profile and Common Pitfalls

Most Common Adverse Events (≥5%):

• Gout flares (89% in early trials) 8
• Infusion reactions
• Nausea
• Contusion/ecchymosis
• Nasopharyngitis
• Constipation
• Chest pain
• Anaphylaxis
• Vomiting 2

Critical Safety Warnings:

BOXED WARNING for anaphylaxis and infusion reactions 2:

• Can occur with ANY infusion, including the first
• Generally manifest within 2 hours but delayed reactions reported
• Risk is significantly higher in patients who have lost therapeutic response (rising serum uric acid) 2

Key Pitfall to Avoid:

Do not continue pegloticase in patients with rising serum uric acid levels—this indicates treatment failure and dramatically increases the risk of severe infusion reactions 2. The 2-consecutive-levels-above-6-mg/dL rule provides a clear stopping point.

Efficacy Data

When patients maintain therapeutic response:

• 42% of biweekly-treated patients achieved primary endpoint (uric acid <6 mg/dL in months 3 and 6) in pooled Phase III trials 9
• Significant improvements in tophi resolution, gout flare frequency, tender joint count, and quality of life parameters 7, 9
• With methotrexate co-therapy, response rates increase to 86-92% 6
• Renal function may improve: 60% of CKD patients showed eGFR increases (mean +11.5 mL/min/1.73 m²) with 87% showing stable or improved CKD stage 6